SAB Biotherapeutics, Inc. 8-K

What Happened

• SAB Biotherapeutics, Inc. (SABS) filed an 8-K reporting the results of its June 18, 2026 Annual Meeting of Stockholders. A quorum was present with 59,349,534 shares represented (approximately 76.12% of 77,966,409 shares entitled to vote).
• Shareholders elected four Class II directors for three-year terms: Dr. David Zaccardelli, Pharm.D.; Katie Ellias; David Link, MBA; and Andrew Moin. Vote totals were:
  • David Zaccardelli: 48,352,114 For, 2,984 Withheld, 10,994,436 Broker Non-Votes
  • Katie Ellias: 48,350,086 For, 5,012 Withheld, 10,994,436 Broker Non-Votes
  • David Link: 44,083,923 For, 4,271,175 Withheld, 10,994,436 Broker Non-Votes
  • Andrew Moin: 44,157,704 For, 4,197,394 Withheld, 10,994,436 Broker Non-Votes
• Shareholders also ratified the appointment of EisnerAmper LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (59,319,363 For; 3,373 Against; 26,798 Abstentions).

Key Details

• Meeting date: June 18, 2026. Quorum: 59,349,534 shares (76.12% of 77,966,409 outstanding).
• Four Class II directors elected to three-year terms.
• Auditor ratified: EisnerAmper LLP — 59,319,363 votes in favor.
• Broker non-votes recorded: 10,994,436 (appeared on director votes).

Why It Matters

• The results confirm the company’s board composition and auditor for fiscal 2026, providing continuity in governance and external financial oversight.
• Vote counts and the significant number of broker non-votes are useful for investors tracking shareholder support levels for management and governance matters.